Metaclipse Therapeutics

Metaclipse Therapeutics is a private, preclinical-stage biotech based in San Diego, pioneering a novel platform of membrane-anchored biological adjuvants. The company's core technology aims to overcome limitations in immunotherapy and vaccinology by co-delivering antigens and adjuvants in a single particulate formulation, designed to elicit potent and specific immune activation. Its lead platform, Membrex™, is an autologous cancer vaccine slated for Phase 1 trials in 2025, while its VaxRex™ platform targets improved vaccines for infectious diseases like influenza and SARS-CoV-2. The company is pre-revenue and funded through grants like an NCI SBIR award, positioning it to advance its pipeline toward clinical proof-of-concept.

Proprietary platform for creating membrane-bound biological adjuvants, involving the physical linkage of cytokine and immunostimulatory proteins to particulate antigen formulations (e.g., tumor-derived membrane vesicles or virus-like particles) to enhance and direct immune responses.

In personalized cancer vaccines, Metaclipse competes with companies like BioNTech, Moderna (mRNA-based), and Gritstone bio. In the adjuvant/vaccine enhancement space, it faces competition from large vaccine makers (GSK, Seqirus) and biotechs focused on novel adjuvant systems. Its differentiation lies in the physical co-delivery of membrane-anchored adjuvants with antigens.